Method of controlled delivery using sub-micron-scale machines

Patent metadata

Field	Value
Publication number	US-10220004-B2
Application number	US-201213550374-A
Country	US
Kind code	B2
Filing date	Jul 16, 2012
Priority date	Jul 14, 2011
Publication date	Mar 5, 2019
Grant date	Mar 5, 2019

Abstract

A method for controlled delivery of a substance into a body includes administering a plurality of containment vessels into the body, in which each of the plurality of containment vessels includes a quantity of the substance loaded therein prior to the administering; and providing a time-varying magnetic field such that the plurality of containment vessels are exposed thereto to cause a release of at least a portion of the substance from the plurality of containment vessels. Each of the plurality of containment vessels has an average outer diameter less than about 1 μm.

First claim

We claim:

1. A method for controlled delivery of a substance into an animal or human body, said method comprising:
administering a plurality of containment vessels into said animal or human body wherein:
each of said containment vessels is comprised of a mesoporous silica nanoparticle defining a plurality of pores and each of said plurality of containment vessels has an average outer diameter less than about 1 μm;
said mesoporous silica nanoparticle encapsulates a plurality of magnetic particles adapted to provide inductive heating when exposed to a time-varying magnetic field;
each of said plurality of containment vessels comprises a quantity of said substance loaded into the pores of said mesoporous silica nanoparticle prior to said administering;
each of said containment vessels comprises a plurality of heat-operable valve assemblies comprising:
i) an alpha-cyclodextrin electrostatically bound to an adamantylethyl trichlorosilane attached to a surface of said vessel; or
ii) a cucurbit[6]uril electrostatically bound to a N-(6-N-aminohexyl)aminomethyltriethoxysilane attached to a surface of said vessel;

wherein said valve assemblies are structured so that in an absence of a time varying magnetic field and at normal temperatures of the animal or human body they retain said substance in said pores after said administering to prevent said quantity of said substance from being released from said pores;
applying said time-varying magnetic field to induce heating of said containment vessels such that said heat-operable valve assemblies release at least a portion of said substance from said pores to deliver said substance into said animal or human body.

2. The method of claim 1 , wherein the average outer diameter of each of said plurality of containment vessels administered is less than about 300 nm.

3. The method of claim 1 , wherein the average outer diameter of each of said plurality of containment vessels administered is less than about 200 nm and greater than about 50 nm.

4. The method of claim 1 , wherein each heat-operable valve assembly comprises a the cucurbit[6]uril electrostatically bound to the N-(6-N-aminohexyl)aminomethyltriethoxysilane attached to the surface of said vessel.

5. The method of claim 1 , where each heat-operable valve assembly comprises the alpha-cyclodextrin electrostatically bound to the adamantylethyl trichlorosilane attached to the surface of said vessel.

6. The method of claim 1 , wherein said substance comprises at least one substance selected from the group consisting of a cosmetic, a therapeutic, a nutritional agent, a diagnostic agent, and an anticancer drug.

7. The method of claim 1 , wherein said substance comprises an anticancer drug.

8. The method of claim 7 , wherein said drug is doxorubicin.

9. The method of claim 7 , wherein said body is a living organism comprising cancer cells.

10. The method of claim 9 , wherein said applying said time-varying magnetic field that induces heating of said containment vessels is performed after said plurality of containment vessels have entered into at least some of said cancer cells within said living organism such that said anticancer drug is released within said at least some cancer cells for cancer treatment.

11. The method of claim 9 , wherein each of said containment vessels further comprises a coating to enhance uptake by said cancer cells preferentially over healthy cells.

12. The method of claim 1 , wherein said magnetic particles comprise super paramagnetic nanoparticles.

13. The method of claim 12 , wherein said super paramagnetic nanoparticles comprise zinc-doped iron oxide nanocrystals.

14. The method of claim 1 , wherein each of said containment vessels further comprises a coating to enhance dispersion within a fluid medium substantially without aggregation.

15. The method of claim 1 , wherein each of said containment vessels further comprises a coating to enhance dispersion within a fluid medium substantially without aggregation.

Assignees

• Zink Jeffrey I
• Thomas Courtney R
• Liong Monty
• Henscheid Sarah Ann
• Cheon Jinwoo
• Lee Jae Hyun
• Ferris Daniel P
• Univ California

Inventors

• Zink Jeffrey I
• Thomas Courtney R
• Liong Monty
• Henscheid Sarah Ann
• Cheon Jinwoo
• Lee Jae-Hyun
• Ferris Daniel P

Classifications

• A61M2205/0288

  Electro-rheological or magneto-rheological materials · CPC title

• A61K9/5094 Primary

  Microcapsules containing magnetic carrier material, e.g. ferrite for drug targeting · CPC title

• A61M2205/368

  by electromagnetic radiation, e.g. IR waves · CPC title

• A61K41/0028 Primary

  Disruption, e.g. by heat or ultrasounds, sonophysical or sonochemical activation, e.g. thermosensitive or heat-sensitive liposomes, disruption of calculi with a medicinal preparation and ultrasounds · CPC title